Business Wire

IN-CUMMINS-INC.

22.9.2022 09:57:25 CEST | Business Wire | Press release

Share
Destination IAA: Cummins unveils new technology for zero-emissions power solutions

Cummins Inc. (NYSE: CMI) is showcasing its platform of zero-emissions technologies this week at the IAA Transportation show, the world's largest mobility show, in Hannover, Germany. A range of new Cummins technologies and the recently acquired Meritor ePowertrain technologies are available publicly together for the first time. With over a century of experience as a global power leader, Cummins is solidifying its commitment to providing comprehensive zero-emissions technology on a global scale.

"Cummins has deep application expertise, and we are uniquely positioned to deliver solutions that truly fit the needs of commercial applications," said Amy Davis, Vice President and President of New Power at Cummins. "Realizing a net-zero future will require a range of technologies. Our extensive zero-emissions portfolio is how we will meet varied customer demands across the hardest-to-abate industries and make the energy transition possible."

One key zero-emissions product Cummins revealed at IAA is its fourth-generation hydrogen fuel cell engine. Designed to meet the duty-cycle, performance and packaging requirements of medium- and heavy-duty trucks and buses, the fuel cell technology is available in 135 kW single and 270 kW dual modules.

Scania in Europe and Daimler Trucks North America have each announced collaborations with Cummins to develop and integrate these next-generation fuel cell engines into demonstrator vehicles. The systems use fourth-generation variable pressure technology to provide higher power density, power nodes and operating temperatures for easier system integration into vehicles. They also have strong operating cycle efficiency and durability for a lower total cost of ownership.

“We know our customers have diverse needs and complicated duty cycles to support, which is why we focus on continued innovation and improvement,” said Amy Adams, Vice President of Fuel Cell and Hydrogen Technologies at Cummins. “We’re developing hydrogen fuel cell technology that demonstrates the capacity and flexibility required to meet or exceed the power needs for on-highway commercial vehicles – proving hydrogen as a viable solution to decarbonize the economy.”

Attendees at IAA will also get the first glimpse of a drivetrain assembled with a newly introduced Cummins lithium iron phosphate (LFP) battery pack, Meritor’s 17xe ePowertrain and Meritor’s Power Control and Accessory System (PCAS). Cummins recently added the ePowertain and PCAS solutions to its portfolio through its acquisition of Meritor. The ePowertrain leverages market-leading technologies in the axle, motor and inverter, delivering performance, efficiency and packaging advantages at a competitive cost. Additionally, the PCAS provides power where needed and control of necessary sub-systems while reducing packaging size and simplifying integration.

Cummins is adding an LFP battery to its line of lithium-ion battery products to expand support of electrified commercial vehicle applications. The LFP solution gives customers access to faster charging and longer-life batteries, targeting the medium-duty truck and school bus markets. By using a multi-chemistry strategy, Cummins is positioned to expand its manufacturing capacity further and diversify its supply chain, providing customers with more cost-effective electrification solutions.

"We are giving customers options to enable them to adapt to a zero-emissions future faster," said Brian Wilson, General Manager of Electrified Components at Cummins. "With the recent acquisition of Meritor and our new multi-chemistry approach, we will be able to tailor our solutions and offer a one-stop-shop for customers' powertrain needs."

Cummins' portfolio includes four batteries, each of which targets a different duty cycle and use case and complement each other. In addition to the LFP option, this includes three nickel manganese cobalt (NMC) batteries – the BP95E, BP74E and BP30E. The BP95E is Cummins’ next-generation solution that prioritizes greater energy density in applications for customers who need more weight-sensitive solutions or have longer ranges. The BP30E is ideal for meeting limited-space applications and rugged demands, and the BP74E is the foundation for Cummins’ BEV innovation and progress.

Download Cummins product photos.

About Cummins Inc.

Cummins Inc., a global power leader, is a corporation of complementary business segments that design, manufacture, distribute and service a broad portfolio of power solutions. The company’s products range from diesel, natural gas, electric and hybrid powertrains, and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, controls systems, air handling systems, automated transmissions, electric power generation systems, batteries, electrified power systems, hydrogen generation and fuel cell products. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 59,900 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment, and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $2.1 billion on sales of $24.0 billion in 2021. See how Cummins is powering a world that is always on by accessing news releases and more information at https://www.cummins.com/always-on.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005980/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye